Machine signal
Active cluster sell — 5 distinct insiders, $22.3M, window ends Sep 17, 2026.
Figures computed from official regulatory filings — .
Analysttarget 109.1 USD (+65%) · consensus 4.5/5 · 19 buy · 3 hold · 0 sell
Ownershipinsiders 3.91% · institutions 99.52% · short 12.3% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for BridgeBio Pharma, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease. In addition, the company engages in developing products for mendelian, oncology, and gene therapy diseases. It has license and collaboration agreements with the Bayer Consumer Care AG, Alexion Pharma International Operations Limited Company, Leland Stanford Junior University, and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
24 buys430 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Kumar Neil | Sell | $601.9K | SEC | ||
| Kumar Neil |
| Sell |
| $89K |
| SEC |
| Kumar Neil | Sell | $679.3K | SEC |
| Kumar Neil | Sell | $152.4K | SEC |
| Kumar Neil | Sell | $154.2K | SEC |
| Kumar Neil | Sell | $100.4K | SEC |
| Kumar Neil | Sell | $8.6K | SEC |
| Kumar Neil | Sell | $1.2M | Unusual size | SEC |
| Kumar Neil | Sell | $1.4M | Unusual size | SEC |
| Kumar Neil | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Kumar Neil | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Kumar Neil | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Kumar Neil | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Trimarchi Thomas | Other | $1.8M | SEC |
| Kumar Neil | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Kumar Neil | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Kumar Neil | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Kumar Neil | Other | $2.9M | Unusual size | SEC |
| Apuli Maricel | Other | $376.5K | SEC |
| Kumar Neil | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Apuli Maricel | Sell | $160.1K | SEC |
| Cook Jennifer E. | Exercise | $287.5K | SEC |
| Ellis Andrea | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ellis Andrea | Sell | $1.4M | SEC |
| Cook Jennifer E. | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |